MYC-RiboTAC

MYC-RiboTAC is a ribonuclease-targeting chimera (RIBOTAC) designed to selectively degrade MYC mRNA by recruiting and locally activating the endogenous ribonuclease RNase L. The molecule consists of two main components: a small-molecule binder that specifically recognizes the internal ribosome entry site (IRES) of MYC mRNA, and a moiety that recruits RNase L to induce targeted RNA cleavage. This dual action leads to decreased levels of both MYC mRNA and protein, resulting in inhibition of cell proliferation and induction of apoptosis in cancer cells. The approach is notable for targeting the "undruggable" oncogene MYC at the RNA level, offering potential as an antitumor therapeutic strategy[1][3][4][5][6].